Tier 3 — preclinical

Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities

Carolina Sandoval-Caballero, Zander Roemer, Catherine M. Kotz, Michael A. Puskarich, Vijayakumar Mavanji, Elizabeth L. Schmidt, Shalamar D. Sibley
Nutrients 2026 18(18):2999

Bibliography

DOI
10.3390/nu18182999
Funding
Funded by the U.S. Department of Veterans Affairs (1I01RX003901) and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK134468).
Competing interests
The authors declared no conflicts of interest.

Study snapshot

DesignPeer-reviewed narrative review with a structured search of PubMed/MEDLINE, Scopus, Web of Science, Google Scholar, ClinicalTrials.gov and the WHO ICTRP.
ModelHuman translational and registered clinical fisetin studies across aging/frailty and chronic age-related diseases.
Sample34 registered clinical studies identified; 6 completed and 4 with results available at the authors' 14 August 2026 registry search.
InterventionMultiple oral fisetin doses, schedules and formulations across registered human studies, including daily fixed doses and intermittent weight-based regimens.
DurationVaried across the 34 clinical studies; the review synthesizes completed and ongoing trials rather than one intervention period.
EndpointsClinical-trial dose and schedule heterogeneity; Fisetin formulation and bioavailability; Aging and frailty outcomes; Inflammation and senescence-related biomarkers; Clinical efficacy and safety gaps

What the study showed, in plain terms

This 2026 review maps the modern human fisetin trial landscape. The authors identified 34 registered clinical studies and found substantial variation in dose, schedule, formulation, population and outcome.

The review is especially useful for interpreting fisetin dosage because it shows that there is no single universal human research regimen. High intermittent weight-based schedules are common in senolytic-oriented work, but fixed daily doses and pharmacokinetic protocols are also being studied.

The authors conclude that clinical evidence remains preliminary and heterogeneous, and that registered dosing protocols should not be treated as proof of efficacy or as established personal dosing recommendations.

Key findings

  • Thirty-four registered clinical fisetin studies were identified across aging/frailty, metabolic disease, cancer, cardiovascular disease, neuroimmune/neurodegenerative disease and other chronic age-related conditions.
  • Only six trials were completed and four had results available at the review's registry search, so the human evidence base remains limited.
  • Dose, treatment schedule, formulation and co-interventions vary substantially across trials, limiting direct comparison.
  • The available evidence does not establish one clinically validated fisetin dose for geroprotection, senolysis or general supplementation.

What this study can and cannot tell us

  • This is a narrative review rather than a systematic review or meta-analysis.
  • Many included studies are registry records without published results, so registration demonstrates research activity rather than efficacy.
  • Trial status, dosing details and available results can change after the review's registry search date.
  • Incomplete reporting of fisetin formulation limits comparisons of nominal dose with actual systemic exposure.

Related papers in the corpus

Tier 3
Fisetin as a senotherapeutic agent — evidence and perspectives for age-related diseases
Tavenier J et al. · Mechanisms of Ageing and Development · 2024
Tier 2
Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study
Illathu Madhavamenon Krishnakumar et al. · Journal of Nutritional Science · 2022
Tier 4
Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial
Juliette Tavenier et al. · Basic & Clinical Pharmacology & Toxicology · 2026
Tier 4
Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity (Fisetin HIGH)
Andersen O et al. · Not applicable - trial registered on ClinicalTrials.gov (not yet published in a peer-reviewed journal) · 2024

Citation network

Articles citing this research paper

8 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology